메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
한국조직공학과 재생의학회 조직공학과 재생의학 조직공학과 재생의학 제12권 제2호
발행연도
2015.1
수록면
80 - 89 (10page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Ever since a technology to reprogram somatic cells into pluripotent stem cells was developed by Dr. Shinya Yamanaka’s group in 2006, its therapeutic potential has been extensively discussed. We now call the reprogrammedembryonic stem cell (ESC)-like cell an ‘induced pluripotent stem cell’ (iPSC). The beauty and power ofthe iPS in human case is that it avoids many ethical issues, in that unlike human ESCs (hESCs), iPSCs do not requiredestroying a human embryo to establish pluripotent cell lines. The iPSC holds many hopes that many human diseasesmay be treatable in the near future. On the other hand, there are still several issues that need to be solved priorto the therapeutic use of iPSCs in humans directly. The biggest hurdle is that, so far, there is lack of ways to completelyexclude tumorigenic iPSC-derived cells. Additionally, there is an issue that immune rejection may occur,even in autologously grafted iPSCs, as was observed in monkey experiment. Nevertheless, iPSCs, combined withgenetic manipulation, hold much promise that iPSCs may be used in cell therapy procedures and as tools for investigatingunderlying mechanisms of human diseases. This review will discuss recent progress in cellular reprogrammingand its potential use in regenerative medicine.

목차

등록된 정보가 없습니다.

참고문헌 (107)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0